



Council of the European Union
General Secretariat

Brussels, 19 February 2019

**Interinstitutional files:
2018/0018(COD)**

WK 2439/2019 INIT

**DOCUMENT PARTIALLY
ACCESSIBLE TO THE
PUBLIC (04.08.2022)**

LIMITE

**PHARM
SAN
MI
COMPET
IA
CODEC**

WORKING PAPER

This is a paper intended for a specific community of recipients. Handling and further distribution are under the sole responsibility of community members.

WORKING DOCUMENT

From: General Secretariat of the Council
To: Working Party on Pharmaceuticals and Medical Devices (HTA)
N° Cion doc.: 5844/18 PHARM 6 SAN 49 MI 61 COMPET 53 IA 43 CODEC 133 + ADD 1 +
ADD 2 + ADD3 + COR 1

Subject: Working Party on Pharmaceuticals and Medical devices on 25 February 2019
- Flash from the Presidency

Delegations will find enclosed the Presidency Flash for the meeting of the Working Party on Pharmaceuticals and Medical devices that will take place on 25 February 2019 (CM 1689/19)

FLASH

Working Party on Pharmaceuticals and Medical devices

25 February 2019, LEX 2, 10.00
(CM 1689/19)

Dear Colleagues,

For our fourth meeting on HTA, we propose to start at 10:00 and finish at approximately 17:00.

We intend to start with a discussion on the revised text for Articles 12 to 17 that you can find in WK 2391/2019. The Presidency prepared it based on the paper we presented at our previous Working Party and the good discussion we had. We expect that this will take us the whole morning and continue in the afternoon.

Then, we intend to turn to the new text on Article 18 put forward by the Netherlands and Belgian delegations, which you can find in WK 2382/2019.

The last point on our agenda will be the discussion that we postponed from our second meeting, namely on:

- Article 24 (Union funding) - we want to see if there are further comments from delegations;
- Article 25 (Commission role) - discuss the tasks of the Commission in its role as the secretariat of the Coordination Group; and
- Article 28 (report) where the Presidency intends, before our discussion, to invite the Commission to explain the differences between this report and the report in Article 29 and their aims

For our Working Party on 25 March we intend to revise if necessary the text for joint scientific consultations and emerging health technologies (Articles 12 to 18), propose a new text for Chapter IV (Support Framework) and discuss conflict of interests and transparency issues.

In case there are any points that you would like to raise under AOB, we kindly invite you to inform the Presidency (presedintie.sanatate@ms.ro) and the Council Secretariat in advance (life.pharmaceuticals@consilium.europa.eu).

The Romanian Presidency health team,

DELETED